XML 36 R23.htm IDEA: XBRL DOCUMENT v3.10.0.1
Description of Business and Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2018
Summary Of Significant Accounting Policies [Line Items]  
Schedule of Potentially Dilutive Common Stock Equivalent Securities

The computation of basic and diluted net loss per share for the nine months ended September 30, 2018 and 2017 excludes the common stock equivalents of the following potentially dilutive securities because their inclusion would be anti-dilutive:

 

 

 

September 30,

 

 

 

2018

 

 

2017

 

Vesting of restricted stock units

 

 

1,169,340

 

 

 

1,147,688

 

Employee stock purchase plan

 

 

97,598

 

 

 

142,888

 

Exercise of common stock options

 

 

11,431,526

 

 

 

7,183,837

 

Conversion of convertible notes into common stock

 

 

3,629,627

 

 

 

814,561

 

Conversion of convertible related party notes into common

   stock

 

 

21,909,541

 

 

 

 

Exercise of common stock warrants

 

 

31,856

 

 

 

31,856

 

Exercise of warrants associated with direct placement

 

 

14,000,000

 

 

 

 

 

 

 

52,269,488

 

 

 

9,320,830

 

 

Accounting Standards Update 2014-09  
Summary Of Significant Accounting Policies [Line Items]  
Schedule of Cumulative Effect of Changes to Condensed Consolidated Balance Sheet for Adoption of New Revenue Guidance

The cumulative effect of the changes made to the condensed consolidated January 1, 2018 balance sheet for the adoption of the new revenue guidance was as follows (in thousands):

 

 

 

Balance at

December 31, 2017

 

 

Adjustments

due to new

revenue

guidance

 

 

 

Balance at

January 1, 2018

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

$

2,789

 

 

$

(111

)

(1)

 

$

2,678

 

Deferred costs from commercial product

   sales

 

 

405

 

 

 

(405

)

(2)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

 

Accrued expenses and other current

   liabilities

 

$

12,449

 

 

$

649

 

(3)

 

$

13,098

 

Deferred revenue, net

 

 

3,038

 

 

 

(3,038

)

(4)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated deficit

 

$

(2,854,898

)

 

$

1,873

 

(5)

 

$

(2,853,025

)

 

 

(1)

To establish a reserve for product returns

 

(2)

To eliminate deferred costs from commercial product sales previously required by the sell-through method

 

(3)

To record additional accrual for estimated voucher payments related to inventory remaining in the distribution channel at January 1, 2018

 

(4)

To eliminate deferred revenue previously required by the sell-through method

 

(5)

To record the net impact of (1)-(4) in opening accumulated deficit

Schedule of Adoption of New Revenue Guidance Impact on Financial Statements

In accordance with the new revenue guidance, the disclosure of the impact of adoption on the condensed consolidated balance sheet and the condensed consolidated statement of operations and cash flows was as follows (in thousands):

 

Condensed Consolidated Balance Sheet

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the nine months ended September 30, 2018

 

 

 

As Reported

 

 

Adjustments

 

 

Balances without

adoption of Topic

606

 

Assets

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

$

2,752

 

 

$

417

 

 

$

3,169

 

Deferred costs from commercial product

   sales

 

 

 

 

 

763

 

 

 

763

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Liabilities

 

 

 

 

 

 

 

 

 

 

 

 

Accrued expenses and other current

   liabilities

 

$

13,434

 

 

$

(588

)

 

$

12,846

 

Deferred revenue, net

 

 

 

 

 

3,601

 

 

 

3,601

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Equity

 

 

 

 

 

 

 

 

 

 

 

 

Accumulated deficit

 

$

(2,930,249

)

 

$

(1,833

)

 

$

(2,932,082

)

 

 

 

 

 

 

 

 

 

 

 

 

 

Condensed Consolidated Statement of

   Operations

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the nine months ended September 30, 2018

 

 

 

As Reported

 

 

Adjustments

 

 

Balances without

adoption of Topic

606

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue - commercial product sales

 

$

11,542

 

 

$

(778

)

 

$

10,764

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

14,406

 

 

$

(975

)

 

$

13,431

 

Net loss

 

 

(77,224

)

 

 

(196

)

 

 

(77,420

)

 

 

 

For the three months ended September 30, 2018

 

 

 

As Reported

 

 

Adjustments

 

 

Balances without

adoption of Topic

606

 

Revenue

 

 

 

 

 

 

 

 

 

 

 

 

Net revenue - commercial product sales

 

$

4,387

 

 

$

(654

)

 

$

3,733

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Expenses

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold

 

$

5,303

 

 

$

(790

)

 

$

4,513

 

Net loss

 

 

(24,168

)

 

 

(137

)

 

 

(24,305

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

For the nine months ended September 30, 2018

 

 

 

As Reported

 

 

Adjustments

 

 

Balances without

adoption of Topic

606

 

Cash Flows from Operating Activities

 

 

 

 

 

 

 

 

 

 

 

 

Net loss

 

 

(77,224

)

 

$

(196

)

 

$

(77,420

)

Change in:

 

 

 

 

 

 

 

 

 

 

 

 

Accounts receivable, net

 

 

(74

)

 

 

111

 

 

 

37

 

Deferred costs from commercial product

   sales

 

 

 

 

 

358

 

 

 

358

 

Accrued expenses and other current

   liabilities

 

 

560

 

 

 

(588

)

 

 

(28

)

Deferred revenue, net

 

 

 

 

 

(563

)

 

 

(563

)

Cash (used in) provided by operating

   activities

 

 

(62,719

)

 

 

(878

)

 

 

(63,597

)